Table 2. Symptom and Physiological Characterization of Enrolled Patients by Screening Result and Chronic Obstructive Pulmonary Disease (COPD) Status.
| Overall (N = 4325)a | No clinically significant COPD (n = 4215)a,b | Clinically significant COPD (n = 110)a,b | ||||
|---|---|---|---|---|---|---|
| Negative screening result (n = 3793) | Positive screening result (n = 532) | Negative screening result (n = 3736) | Positive screening result (n = 479) | Negative screening result (n = 57) | Positive screening result (n = 53) | |
| COPD Assessment Testc | ||||||
| Score, mean (SD) | 7.6 (6.0) | 16.2 (8.1) | 7.6 (6.0) | 16.2 (8.2) | 10.3 (5.9) | 16.0 (7.9) |
| Score ≥10, No. (%) | 1159 (30.6) | 411 (77.3) | 1131 (30.3) | 368 (76.8) | 28 (49.1) | 43 (81.1) |
| Walks slower than others or stops to catch breath (modified Medical Research Council dyspnea score ≥2), No. (%)d | 417 (11.0) | 234 (44.1) | 405 (10.9) | 217 (45.4) | 12 (21.1) | 17 (32.1) |
| Acute respiratory illness within past 12 mo, No. (%)e | 274 (7.2) | 131 (24.7) | 257 (6.9) | 107 (22.4) | 17 (29.8) | 24 (45.3) |
| FEV1:FVC, mean (SD), %f | 78.7 (6.2) | 75.3 (9.1) | 79.0 (5.7) | 77.1 (7.0) | 60.0 (7.9) | 59.0 (9.8) |
| FVC, mean (SD), % of predicted valuef | 89.8 (14.8) | 80.7 (16.4) | 90.0 (14.6) | 81.6 (16.6) | 73.5 (16.3) | 73.3 (12.7) |
| FEV1, mean (SD), % of predicted valuef | 91.5 (15.6) | 78.3 (17.4) | 92.0 (15.0) | 80.7 (16.1) | 57.7 (14.6) | 56.3 (12.6) |
| Disease classification, No. (%) | ||||||
| No COPD | 3567 (94.0) | 425 (79.9) | 3567 (95.5) | 425 (88.7) | ||
| COPD that was not clinically significant | 169 (4.5) | 54 (10.2) | 169 (4.5) | 54 (11.3) | ||
| Clinically significant COPD | 57 (1.5) | 53 (10.0) | 57 (100) | 53 (100) | ||
| GOLD classification, No. (%)g | ||||||
| No COPD | 3567 (94.0) | 425 (79.9) | 3567 (95.5) | 425 (88.7) | ||
| Group A (COPD Assessment Test score <10 and no or a mild exacerbation history) | 146 (3.8) | 28 (5.3) | 120 (3.2) | 18 (3.8) | 26 (45.6) | 10 (18.9) |
| Group B (COPD Assessment Test score ≥10 and no or a mild exacerbation history) | 72 (1.9) | 66 (12.4) | 49 (1.3) | 36 (7.5) | 23 (40.4) | 30 (56.6) |
| Group C (COPD Assessment Test score <10 and a moderate or severe exacerbation history) | 3 (0.1) | 0 | 3 (5.3) | 0 | ||
| Group D (COPD Assessment Test score ≥10 and a moderate or severe exacerbation history) | 5 (0.1) | 13 (2.4) | 5 (8.8) | 13 (24.5) | ||
| Post hoc classification based on spirometry results and respiratory symptom assessment, No. (%) | ||||||
| A normal spirometry resulth and COPD Assessment Test score <10 | 2147 (56.6) | 60 (11.3) | 2147 (57.5) | 60 (12.5) | ||
| A normal spirometry result, COPD Assessment Test score ≥10, and never smoked | 418 (11.0) | 76 (14.3) | 418 (11.2) | 76 (15.9) | ||
| A normal spirometry result, COPD Assessment Test score ≥10, and formerly or currently smoked | 409 (10.8) | 109 (20.5) | 409 (11.0) | 109 (22.8) | ||
| Preserved ratio impaired spirometryi | 591 (15.6) | 180 (33.8) | 591 (15.8) | 180 (37.6) | ||
| Any spirometry-defined COPD | 226 (6.0) | 107 (20.1) | 169 (4.5) | 54 (11.3) | 57 (100) | 53 (100) |
Data were missing for less than 0.5% of patients in each column.
COPD was defined by a postbronchodilator ratio of forced expiratory volume in the first second of expiration to forced vital capacity (FEV1:FVC) less than 0.70 or a prebronchodilator FEV1:FVC less than 0.65 in patients who did not complete postbronchodilator spirometry, and was considered clinically significant if the patient also had either 1 or more acute respiratory illnesses within the past 12 months or an FEV1 less than 60% of the predicted value.
Scores range from 0 to 40; higher scores indicate worse symptoms. A score of 10 or greater represents significant respiratory symptom burden.8
Scores range from 0 to 4; higher scores indicate worse breathlessness.
Patients were asked, “Over the last 12 months, have you had episodes of chest troubles (cough, phlegm, or shortness of breath) requiring treatment with antibiotics and/or steroids?”
Measured postbronchodilator for patients who completed postbronchodilator spirometry. For all others, it was measured prebronchodilator.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) groupings are based on published standards.8
No COPD and FEV1 was 80% or greater of the predicted value.
No COPD and FEV1 was less than 80% of the predicted value.